Nykredit A S Purchases Shares of 8,713 Exelixis, Inc. $EXEL

Nykredit A S acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 8,713 shares of the biotechnology company’s stock, valued at approximately $474,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in EXEL. BlackRock Inc. bought a new stake in Exelixis during the second quarter worth approximately $1,581,991,000. AQR Capital Management LLC increased its holdings in shares of Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after buying an additional 4,477,029 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock valued at $265,379,000 after buying an additional 94,218 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Exelixis by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock valued at $184,391,000 after acquiring an additional 39,920 shares during the last quarter. Finally, Morgan Stanley lifted its position in shares of Exelixis by 31.0% during the 4th quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock valued at $184,378,000 after acquiring an additional 995,949 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Transactions at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This represents a 37.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EXEL. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $56.00 target price on shares of Exelixis in a research report on Thursday, July 2nd. Zacks Research upgraded Exelixis from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. Stifel Nicolaus increased their price target on Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research report on Thursday, August 6th. Finally, Morgan Stanley lifted their price target on Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $50.07.

Exelixis Stock Performance

NASDAQ EXEL opened at $57.67 on Wednesday. The firm’s 50 day moving average price is $55.23 and its two-hundred day moving average price is $49.74. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $59.72. The stock has a market cap of $14.29 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 1.76 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to analyst estimates of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 earnings per share. On average, research analysts forecast that Exelixis, Inc. will post 3.19 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.